The Future Is Now: 2 Medical Diagnostic AI Stocks to Snap Up

Core Insights - Interest in artificial intelligence (AI) is significantly benefiting medical diagnostic stocks, particularly Butterfly Network and GE HealthCare Technologies [1] - AI enhances medical diagnostics by reducing errors, preventing costs, and improving patient outcomes [1] Butterfly Network - Butterfly Network utilizes capacitive micromachined ultrasonic transducer (CMUT) technology, allowing a single chip to replace traditional ultrasound hardware [3] - The company transitioned from a hardware-only model to a software and AI platform, achieving its first quarter of positive cash flow after years of losses [3] - Butterfly Network's stock has increased over 9% in 2026 and over 48% in the past year [3] - The company reported fourth-quarter revenue of $31.5 million, a 44% year-over-year increase, with software and services contributing 43% of total revenue [6] - The devices are priced at $3,000 to $4,000, significantly lower than traditional ultrasound machines [5] GE HealthCare Technologies - GE HealthCare is shifting focus from medical-device hardware to AI software, with a primary strategy centered around the Edison Digital Health Platform [7] - The company’s shares have decreased over 11% this year and over the past 12 months, despite being over 30 times larger than Butterfly Network [7] - GE HealthCare reported revenue of $21.6 billion and EPS of $4.55 in 2025, with projections for organic revenue growth of 3% to 4% and adjusted EPS growth of 7.9% to 12.3% in 2026 [10] - The latest AI application, Photonova Spectra, has received FDA clearance for improved CT scans in cardiology [9] - GE HealthCare's healthy cash flow supports debt reduction and acquisitions of smaller AI and digital health startups [13] Investment Considerations - Butterfly Network presents higher growth potential but is riskier due to its lack of profitability and financial cushion [12] - GE HealthCare is a more established and profitable company, trading at around 14 times earnings and 3 times sales, making it a potentially safer investment [13]